Highest Analyst Upside Stocks
SUPN is part of our highest analyst upside stock list, indicating analysts have a price target way above the current price.
SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Price & Overview
NASDAQ:SUPN • US8684591089
Current stock price
49.12 USD
-2.13 (-4.16%)
At close:
49.12 USD
0 (0%)
After Hours:
The current stock price of SUPN is 49.12 USD. Today SUPN is down by -4.16%. In the past month the price increased by 3.68%. In the past year, price increased by 58.47%.
SUPN Key Statistics
52-Week Range29.16 - 59.68
Current SUPN stock price positioned within its 52-week range.
1-Month Range48.235 - 52.69
Current SUPN stock price positioned within its 1-month range.
- Market Cap
- 2.828B
- P/E
- 15.40
- Fwd P/E
- 25.04
- EPS (TTM)
- 3.19
- Dividend Yield
- N/A
SUPN Stock Performance
Today
-4.16%
1 Week
+1.90%
1 Month
+3.68%
3 Months
+5.82%
Longer-term
6 Months -3.35%
1 Year +58.47%
2 Years +69.63%
3 Years +38.52%
5 Years +67.68%
10 Years +197.55%
SUPN Stock Chart
SUPN Stock Screens
SUPN currently appears in the following ChartMill screener lists.
SUPN Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to SUPN. When comparing the yearly performance of all stocks, SUPN is one of the better performing stocks in the market, outperforming 84.68% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
SUPN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to SUPN. SUPN has only an average score on both its financial health and profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SUPN Earnings
On February 24, 2026 SUPN reported an EPS of 0.84 and a revenue of 211.57M. The company beat EPS expectations (142.21% surprise) and beat revenue expectations (6.37% surprise).
Next Earnings DateMay 12, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported$0.84
Revenue Reported211.572M
EPS Surprise 142.21%
Revenue Surprise 6.37%
SUPN Forecast & Estimates
12 analysts have analysed SUPN and the average price target is 64.43 USD. This implies a price increase of 31.17% is expected in the next year compared to the current price of 49.12.
For the next year, analysts expect an EPS growth of -38.5% and a revenue growth 23.14% for SUPN
Analysts
Analysts83.33
Price Target64.43 (31.17%)
EPS Next Y-38.5%
Revenue Next Year23.14%
SUPN Groups
Sector & Classification
SUPN Financial Highlights
Over the last trailing twelve months SUPN reported a non-GAAP Earnings per Share(EPS) of 3.19. The EPS increased by 8.14% compared to the year before.
Income Statements
Revenue(TTM)718.95M
Net Income(TTM)-38.55M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.65% | ||
| ROE | -3.63% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%12%
Sales Q2Q%21.48%
EPS 1Y (TTM)8.14%
Revenue 1Y (TTM)8.63%
SUPN Ownership
Ownership
Inst Owners103.51%
Shares57.58M
Float55.04M
Ins Owners4.36%
Short Float %8.24%
Short Ratio6.2
SUPN Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.83 | 869.14B | ||
| JNJ | JOHNSON & JOHNSON | 17.83 | 555.642B | ||
| MRK | MERCK & CO. INC. | 22.11 | 289.223B | ||
| PFE | PFIZER INC | 9.14 | 156.544B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.38 | 120.728B | ||
| ZTS | ZOETIS INC | 16.71 | 51.606B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.443B | ||
| VTRS | VIATRIS INC | 5.91 | 17.315B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.49 | 11.825B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.651B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.206B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.087B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.11 | 4.929B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SUPN
Company Profile
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 778 full-time employees. The company went IPO on 2010-12-28. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. The company also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
Company Info
IPO: 2010-12-28
SUPERNUS PHARMACEUTICALS INC
9715 Key West Avenue
Rockville MARYLAND 20850 US
CEO: JACK A. KHATTAR
Employees: 778
Phone: 13018382500
SUPERNUS PHARMACEUTICALS INC / SUPN FAQ
Can you describe the business of SUPERNUS PHARMACEUTICALS INC?
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 778 full-time employees. The company went IPO on 2010-12-28. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. The company also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
What is the current price of SUPN stock?
The current stock price of SUPN is 49.12 USD. The price decreased by -4.16% in the last trading session.
Does SUPERNUS PHARMACEUTICALS INC pay dividends?
SUPN does not pay a dividend.
What is the ChartMill technical and fundamental rating of SUPN stock?
SUPN has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the GICS sector and industry of SUPN stock?
SUPERNUS PHARMACEUTICALS INC (SUPN) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the growth outlook for SUPERNUS PHARMACEUTICALS INC?
The Revenue of SUPERNUS PHARMACEUTICALS INC (SUPN) is expected to grow by 23.14% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is SUPERNUS PHARMACEUTICALS INC worth?
SUPERNUS PHARMACEUTICALS INC (SUPN) has a market capitalization of 2.83B USD. This makes SUPN a Mid Cap stock.